VRTX240816P425000
- 0.05
- 0.000.00%
Vertex Pharmaceuticals Newsroom
10 Health Care Stocks With Whale Alerts In Today's Session
Vertex Pharmaceuticals Insider Sold Shares Worth $602,447, According to a Recent SEC Filing
Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals
"Sister Muzi" has added positions to Robinhood for two straight days and reduced shareholding in Zoom.
Recently, Cathie Wood, also known as "Mudaojie", made a series of significant trades through her ARK Investment Management company, including increasing holdings in Robinhood and reducing holdings in Zoom. ARK Investment Management decided to increase holdings in Robinhood stocks after the impressive Q2 performance published by the trading platform. On Thursday, local time, ARK Investment Management used its ARK Fintech Innovation ETF ARKF and ARK Next Generation Internet, which are both internet plus-related, to carry out these transactions.
The Zacks Analyst Blog Vertex Pharmaceuticals CRISPR and Moderna
Here's How to Play Vertex (VRTX) Stock After Q2 Loss, Price Dip
The GLP-1 Makers to Add to Your Portfolio: Tema ETFs CEO
Top Research Reports for NVIDIA, Home Depot & Vertex Pharmaceuticals
BofA Upgrades Editas to Buy, Cites Reni-cel Progress
Insider Sale at Vertex Pharmaceuticals Inc (VRTX) by EVP and CMO Carmen Bozic
Express News | Reported Earlier, Vertex Secures NHS England Reimbursement For Groundbreaking CASGEVY Therapy For Transfusion-Dependent Beta Thalassemia
Express News | Vertex Pharmaceuticals - Eligible Transfusion-Dependent Beta Thalassemia (Tdt) Patients in England Will Be Able to Access Therapy From Today
Express News | Vertex Announces Casgevy™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England
Vertex Announces CASGEVY Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here Is What You Need to Know
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Investing in Biotech Outside of Weight-loss Drugs
HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $600
Unusual Options Activity: HAL, DAL and Others Attract Market Bets, HAL V/OI Ratio Reaches 687.9
Vertex Downgraded at Barclays Due to Valuation